Paoli, PA, March 3, 2015 – Results of the recent study, Results From a Set of 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection, were presented as part of the general poster session at the 32nd Annual Miami Breast Cancer Conference last week.
The study, conducted by Moshe Papa, MD, FACS, Professor of Surgery at the Sackler School of Medicine at Tel Aviv University, reports an analysis of MarginProbe’s efficiency and accuracy when used consecutively to examine excised breast tissue during a lumpectomy. The device was used in 100 consecutive lumpectomy procedures between June 2013 and October 2014. Last year, leading breast cancer national societies announced new guidelines for surgical outcomes that require bringing the patient back for a second procedure: “cancer on ink,” according to pathology. According to these guidelines, 64 percent of such repeat procedures were spared by use of the MarginProbe in the study. Overall, eight patients underwent a re-excision lumpectomy procedure. Only three out of 100 patients underwent a re-excision procedure due to failed detection of the margins on the main specimen.
“The fact that only three out of 100 patients had to undergo a re-excision procedure due to failed detection of cancer on the margins is impressive,” said Dr. Papa. “The device was only used on the main specimen in this study so it would be interesting to do a study using MarginProbe on the shavings to determine if the total re-excision rate could be reduced even further.”
“We are thrilled to present the results of yet another MarginProbe study that showcase its effectiveness in reducing the number of re-excisions,” said Dan Hashimshony PhD, CEO and founder of Dilon Devices. “As we grow, and surgeons across the country continue to adopt MarginProbe, we become closer to our goal of drastically reducing repeat surgeries for women undergoing lumpectomies.”
The study results were conclusive in determining that MarginProbe is an easy tool to use for positive margin detection. When combined with intraoperative and clinical information from specimen radiology and palpitation, the majority of positive margins on the main specimen were identified and re-excision rates were reduced.
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.
Dilon Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.dunemedical.com.